Protagonist reports Q4 profit, $300M Takeda deal extends cash runway through 2027

Protagonist Therapeutics, Inc

Entered worldwide Takeda collaboration for rusfertide; $300M upfront, US profit share, opt-out up to $400M.
Q4 net income $27.3M ($0.45 EPS) vs loss $34.2M in Q4 2022; full year loss $79M improved from $127.4M.
Cash $341.6M; runway extended through Q4 2027 including $300M Takeda upfront.
Earned $60M in JNJ-2113 milestones from J&J in Q4; VERIFY Phase 3 enrollment on track for Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Protagonist Therapeutics, Inc reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 27, 2024, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-24-028208

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.